Anupam Rasayan India Ltd releases Q2/H1 FY27 presentation, reporting Q2 consolidated EBITDA of ₹202 crore and 25% margin
- Q2 consolidated revenue was ₹821 crore; revenue from operations rose about 10% year on year to ₹806 crore.
- EBITDA grew 41% year on year to ₹202 crore; net profit rose 14% to ₹65 crore.
- Q2 FY26 revenue from operations included ₹180 crore of one-off sales; the company completed its acquisition of a 50.07% controlling stake in Bliss GVS Pharma on September 28, 2026.
